{"id":1390,"date":"2025-03-12T14:35:17","date_gmt":"2025-03-12T14:35:17","guid":{"rendered":"https:\/\/fhucare.com\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/"},"modified":"2025-12-25T19:00:48","modified_gmt":"2025-12-25T18:00:48","slug":"evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6","status":"publish","type":"post","link":"https:\/\/fhucare.com\/fr\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/","title":{"rendered":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer #TIJC6"},"content":{"rendered":"<h4><span style=\"color: #000080\"><strong>WEBINAR Transdisciplinary Immunology Journal Club<\/strong><\/span><br \/><strong><span style=\"background-color: #000000;color: #ffcc00\">Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Lyu A &amp; al. Nature. 2025&nbsp;<\/span><\/strong><br \/>With Dr Simon COIBA<br \/>Thursday, April 24, 2025 from 5:00 PM to 6:00 PM<\/h4>\n<\/p>\n<p>&nbsp;<\/p>\n<\/p>\n<p>Revoir en Replay TIJC#5<br \/><strong>Hallmarks of CD8+ T cell dysfunction are established within hours of tumor antigen encounter before cell division (Nat Immunol.)<\/strong> par le <a href=\"https:\/\/youtu.be\/zu9ce70MxEA?si=3FY0IdtlLkSEZLWb&amp;t=1\">Dr Matthieu Roulleau Dugage, disponible ICI<br \/><\/a><\/p>\n<\/p>\n<p>Revoir en Replay TIJC#1<br \/><a href=\"https:\/\/youtu.be\/1k7rr2e4HxQ?si=rfk5Vm8aY4OLnY9f&amp;t=1\"><strong>JAK Inhibitors and Cancer: Friend or Foe?&nbsp;<\/strong>Par le Dr Samuel Bitoun, disponible ICI<\/a><\/p>\n<\/p>\n<p>Revoir en Replay TIJC#2<br \/><strong>The type 2 cytokine Fc\u2013IL-4 revitalizes exhausted CD8+ T cells against cancer, Nature 2024.&nbsp;<\/strong>P<a href=\"https:\/\/youtu.be\/j6wn-f__GwU?si=NzuWOsK-geE3XuRN\">ar le Dr Fran\u00e7ois-Xavier Danlos, disponible ICI<\/a><\/p>\n<\/p>\n<p>Revoir en Replay TIJC#3<br \/><strong>Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis, JExpMed.&nbsp;<br \/><\/strong>With Dr Marie ROBERT.<strong>&nbsp;REPLAY HERE !&nbsp;<\/strong><\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>WEBINAR Transdisciplinary Immunology Journal ClubEvolution of myeloid-mediated immunotherapy resistance in prostate cancer. Lyu A &amp; al. Nature. 2025&nbsp;With Dr Simon COIBAThursday, April 24, 2025 from 5:00 PM to 6:00 PM &nbsp; Revoir en Replay TIJC#5Hallmarks of CD8+ T cell dysfunction are established within hours of tumor antigen encounter before cell division (Nat Immunol.) par le [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1391,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"event_date":"Thursday, April 24, 2025 ","event_location":"online webinar","event_time":"5:00 PM to 6:00 PM","footnotes":""},"categories":[10],"tags":[],"class_list":["post-1390","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-event"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evolution of myeloid-mediated immunotherapy resistance in prostate cancer #TIJC6 - FHU CARE\u00b2<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fhucare.com\/fr\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer #TIJC6 - FHU CARE\u00b2\" \/>\n<meta property=\"og:description\" content=\"WEBINAR Transdisciplinary Immunology Journal ClubEvolution of myeloid-mediated immunotherapy resistance in prostate cancer. Lyu A &amp; al. Nature. 2025&nbsp;With Dr Simon COIBAThursday, April 24, 2025 from 5:00 PM to 6:00 PM &nbsp; Revoir en Replay TIJC#5Hallmarks of CD8+ T cell dysfunction are established within hours of tumor antigen encounter before cell division (Nat Immunol.) par le [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fhucare.com\/fr\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/\" \/>\n<meta property=\"og:site_name\" content=\"FHU CARE\u00b2\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-12T14:35:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-25T18:00:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fhucare.com\/wp-content\/uploads\/2025\/03\/TIJC6.png\" \/>\n\t<meta property=\"og:image:width\" content=\"756\" \/>\n\t<meta property=\"og:image:height\" content=\"567\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"adm-fhuc2-la\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"adm-fhuc2-la\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\\\/\"},\"author\":{\"name\":\"adm-fhuc2-la\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#\\\/schema\\\/person\\\/2e9ff2878c5ffade65bdda120c97b8e0\"},\"headline\":\"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer #TIJC6\",\"datePublished\":\"2025-03-12T14:35:17+00:00\",\"dateModified\":\"2025-12-25T18:00:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\\\/\"},\"wordCount\":140,\"publisher\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/TIJC6.png\",\"articleSection\":[\"Event\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\\\/\",\"url\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\\\/\",\"name\":\"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer #TIJC6 - FHU CARE\u00b2\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/TIJC6.png\",\"datePublished\":\"2025-03-12T14:35:17+00:00\",\"dateModified\":\"2025-12-25T18:00:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/TIJC6.png\",\"contentUrl\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/TIJC6.png\",\"width\":756,\"height\":567},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer #TIJC6\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/\",\"name\":\"FHU CARE\u00b2\",\"description\":\"Innovations in Autoimmunity, Cancer &amp; Immunotherapies\",\"publisher\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#organization\"},\"alternateName\":\"CARE2\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#organization\",\"name\":\"FHU CARE\u00b2\",\"alternateName\":\"CARE2\",\"url\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/CARE2-COULEUR.svg\",\"contentUrl\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/CARE2-COULEUR.svg\",\"caption\":\"FHU CARE\u00b2\"},\"image\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/fhucare\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@fhucare\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#\\\/schema\\\/person\\\/2e9ff2878c5ffade65bdda120c97b8e0\",\"name\":\"adm-fhuc2-la\",\"sameAs\":[\"https:\\\/\\\/fhucare.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer #TIJC6 - FHU CARE\u00b2","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fhucare.com\/fr\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/","og_locale":"fr_FR","og_type":"article","og_title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer #TIJC6 - FHU CARE\u00b2","og_description":"WEBINAR Transdisciplinary Immunology Journal ClubEvolution of myeloid-mediated immunotherapy resistance in prostate cancer. Lyu A &amp; al. Nature. 2025&nbsp;With Dr Simon COIBAThursday, April 24, 2025 from 5:00 PM to 6:00 PM &nbsp; Revoir en Replay TIJC#5Hallmarks of CD8+ T cell dysfunction are established within hours of tumor antigen encounter before cell division (Nat Immunol.) par le [&hellip;]","og_url":"https:\/\/fhucare.com\/fr\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/","og_site_name":"FHU CARE\u00b2","article_published_time":"2025-03-12T14:35:17+00:00","article_modified_time":"2025-12-25T18:00:48+00:00","og_image":[{"width":756,"height":567,"url":"https:\/\/fhucare.com\/wp-content\/uploads\/2025\/03\/TIJC6.png","type":"image\/png"}],"author":"adm-fhuc2-la","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"adm-fhuc2-la","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fhucare.com\/fr\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/#article","isPartOf":{"@id":"https:\/\/fhucare.com\/fr\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/"},"author":{"name":"adm-fhuc2-la","@id":"https:\/\/fhucare.com\/fr\/#\/schema\/person\/2e9ff2878c5ffade65bdda120c97b8e0"},"headline":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer #TIJC6","datePublished":"2025-03-12T14:35:17+00:00","dateModified":"2025-12-25T18:00:48+00:00","mainEntityOfPage":{"@id":"https:\/\/fhucare.com\/fr\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/"},"wordCount":140,"publisher":{"@id":"https:\/\/fhucare.com\/fr\/#organization"},"image":{"@id":"https:\/\/fhucare.com\/fr\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/#primaryimage"},"thumbnailUrl":"https:\/\/fhucare.com\/wp-content\/uploads\/2025\/03\/TIJC6.png","articleSection":["Event"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/fhucare.com\/fr\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/","url":"https:\/\/fhucare.com\/fr\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/","name":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer #TIJC6 - FHU CARE\u00b2","isPartOf":{"@id":"https:\/\/fhucare.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fhucare.com\/fr\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/#primaryimage"},"image":{"@id":"https:\/\/fhucare.com\/fr\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/#primaryimage"},"thumbnailUrl":"https:\/\/fhucare.com\/wp-content\/uploads\/2025\/03\/TIJC6.png","datePublished":"2025-03-12T14:35:17+00:00","dateModified":"2025-12-25T18:00:48+00:00","breadcrumb":{"@id":"https:\/\/fhucare.com\/fr\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fhucare.com\/fr\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/fhucare.com\/fr\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/#primaryimage","url":"https:\/\/fhucare.com\/wp-content\/uploads\/2025\/03\/TIJC6.png","contentUrl":"https:\/\/fhucare.com\/wp-content\/uploads\/2025\/03\/TIJC6.png","width":756,"height":567},{"@type":"BreadcrumbList","@id":"https:\/\/fhucare.com\/fr\/event\/evolution-of-myeloid-mediated-immunotherapy-resistance-in-prostate-cancer-tijc6\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/fhucare.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer #TIJC6"}]},{"@type":"WebSite","@id":"https:\/\/fhucare.com\/fr\/#website","url":"https:\/\/fhucare.com\/fr\/","name":"FHU CARE\u00b2","description":"Innovations in Autoimmunity, Cancer &amp; Immunotherapies","publisher":{"@id":"https:\/\/fhucare.com\/fr\/#organization"},"alternateName":"CARE2","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fhucare.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/fhucare.com\/fr\/#organization","name":"FHU CARE\u00b2","alternateName":"CARE2","url":"https:\/\/fhucare.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/fhucare.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/fhucare.com\/wp-content\/uploads\/2025\/11\/CARE2-COULEUR.svg","contentUrl":"https:\/\/fhucare.com\/wp-content\/uploads\/2025\/11\/CARE2-COULEUR.svg","caption":"FHU CARE\u00b2"},"image":{"@id":"https:\/\/fhucare.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/in\/fhucare\/","https:\/\/www.youtube.com\/@fhucare\/"]},{"@type":"Person","@id":"https:\/\/fhucare.com\/fr\/#\/schema\/person\/2e9ff2878c5ffade65bdda120c97b8e0","name":"adm-fhuc2-la","sameAs":["https:\/\/fhucare.com"]}]}},"_links":{"self":[{"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/posts\/1390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/comments?post=1390"}],"version-history":[{"count":2,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/posts\/1390\/revisions"}],"predecessor-version":[{"id":2384,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/posts\/1390\/revisions\/2384"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/media\/1391"}],"wp:attachment":[{"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/media?parent=1390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/categories?post=1390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/tags?post=1390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}